Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Jetstar to Charge for Overhead Cabin Bags From February 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
SANTA MONICA, Calif., March 19, 2018 -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, announced today that Roger Crystal, MD., President and Chief Executive Officer, will provide a corporate overview at the Oppenheimer 28th Annual Healthcare Conference, being held March 20-21 at the Westin Grand Central Hotel in New York City.
| Presentation Details | ||
| Date: | Wednesday, March 21 | |
| Time: | 1:00pm Eastern Time | |
| Location: | Westin Grand Central Hotel, Track 3 | |
| Webcast: | https://ir.opiant.com | |
About Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc. is a specialty pharmaceutical company developing pharmacological treatments for addictions. NIDA, a division of the NIH, describes these disorders as chronic relapsing brain diseases which burden society at both the individual and community levels. With its innovative opioid antagonist nasal delivery technology, Opiant is positioned to become a leader in these treatment markets. Its first product, NARCAN® Nasal Spray, is approved for marketing in the U.S. and Canada by the company’s partner, Adapt Pharma Operations Limited. For more information please visit: www.opiant.com.
CONTACTS:
Dan Ferry
Managing Director
LifeSci Advisors, LLC
[email protected]
(617) 535-7746
